Ruti Aga: Six Years, and the Forged Prescription That Closed Her Only Defence

The half marathon Ruti Aga won in China in March has no time recorded in any official document that has reached me. No field depth, no five-kilometre splits. What the Athletics Integrity Unit statement on Thursday records is not the race but the arithmetic that followed it — two years for the presence of a prohibited substance, four years for misleading the investigation and producing a forged document. Six years in total, effective from 10 September, backdated to her provisional suspension.

For a 32-year-old marathoner, that arithmetic is the end of a career. But the crisis is not in the drug that was found in her sample. It is in the piece of paper manufactured to defend it.

Aga's name is familiar to anyone who tracks the Marathon Majors. The 2026 Tokyo Marathon title, second place in Berlin 2026 — my ledger has that run at 2:18:34, though the figure still needs re-checking against the official record — and three second-place finishes across the Majors in total. I watched that 2026 Tokyo morning three times, because I wanted to see how her pace held after thirty kilometres. The answer was unambiguous: without panic, without trying to win the race inside one kilometre. That record now sits in an odd condition. The sanction is anchored to the March race, and the statement does not specify which results were annulled. Standard AIU practice voids the result and prize money from the competition where the sample was collected; earlier results fall only if prior use is proven. So the 2026 Tokyo title survives on paper, for now.

The Chinese half marathon circuit has to be understood, because that is where the case was built. In the months between Majors it is a tier where the appearance fee is good, the risk feels small and the annual race count can be kept low. For a 2:18–2:20 marathoner the model is rational: two or three Majors, and Asian label races in between. That same tier has become the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races. Ethiopia's women's marathon depth is such that the removal of one 2:18 performer does not register in national-team arithmetic at all. That is a hard sentence, and a necessary one: this case does not change the competitive picture of the event, it changes the governance picture.

Now the part where much of the reporting went wrong. Methylprednisolone was described as a prohibited steroid and said to be classed by WADA as performance-enhancing. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid, WADA Prohibited List class S9, not S1. And S9 is prohibited in-competition only, by injectable, oral or rectal routes. A therapeutic knee injection given out of competition is not a violation in itself; it becomes one only if residues are present in-competition. That technical distinction matters because the defence rested on it. Intra-articular treatment for knee synovitis is ordinary sports medicine in distance runners; the date of the injection, the route and the washout period could all have been established, provided real medical records existed.

No defence was mounted. A prescription was manufactured. According to the AIU, the document was written by a family member with no medical registration, who claimed to have used an old prescription pad from a former workplace, and the clinic named on the form did not exist — the clinic disowned the document in explicit terms. Three independent verifications, three failures. The twist is that the drug gave her no performance benefit at all, and the paper invented to protect her is precisely what removed her from the sport for six years.

The sanction arithmetic is legible. Two years for presence, the standard outcome where intent is not established in a Specified Substance case; four years for tampering, the Code's default. One thing can be read from that sum: the panel rejected the no-significant-fault mitigation that would otherwise have reduced the first element. Backdating the ban to the provisional suspension date is a procedural credit, not a discount — she could not have raced in that window anyway.

The picture of medical support is more telling still. The person acting as doctor was a relative with no registration. No credentialed team physician is mentioned, no TUE application, no observance of route-specific washout. When an athlete has no genuine medical file, fabricating one becomes the next logical step; this case is about an empty health-governance shell, not about a drug. And the four-year tampering sanction rests not only on a document but on an interview — statements given under questioning raised the penalty. Language and interpretation in AIU interviews with East African runners have been a recurring point of contention. That is not an excuse; it is a procedural point an appeal can test.

The counter-intuitive read is that framing this as a doping bust is both easy and wrong. There is no established evidence that glucocorticoids improve endurance performance; what the six years actually punishes is an administrative failure, not a visible dishonesty. Comparing this case to anabolic-steroid cases would therefore be dishonest — the sanction shape may look the same, the offence is nothing like it. The second easy relief is to call this one athlete's isolated error. I do not read it that way. The structure visible here is an injured marathoner under pressure to protect appearance-fee income, a glucocorticoid as the cheapest available tool for masking pain, and an informal medical network around her with no verification layer. The forged prescription is downstream of that gap, not the cause of it.

One thing worth recording plainly: the record that survives this investigation is genuine. The 2026 Tokyo title and the three Major runner-up finishes were not favours, and absent proof of earlier use they will stay in the books. Erasing an athlete's entire past is not the job of an investigation; deciding from what date results are void is. In this case that date is the March race, and the statement does not say so clearly.

Two things to watch. The enforcement frontier has shifted from detection to document verification; over the next two seasons there will be more cases where the underlying violation is small and the sanction is large, because the sanction attaches to paperwork. And the appeal window is open, but a forged-document finding is document-based and extremely hard to overturn.

The question left in my notebook is this: who decided the treatment plan for that knee in March, and who advised that the prescription be produced in that form? The statement names one family member. Whether an agent, a manager or a camp was examined is not written anywhere. The day that gets written, this stops being one runner's mistake and becomes a system report. The race in China has no recorded time. The six years do.